Roaa Emad Ali
Department of Medical Chemistry, College of Medicine, University of Al -Qadisiyah, Al-Diwaniyah, Iraq
Ajile A. Alzamily
Department of Medical Chemistry, College of Medicine, University of Al -Qadisiyah, Al-Diwaniyah, Iraq
Osama M. Al Obaidi
Department of biotechnology College of biotechnology, university of Al-Qadisiyah, Al-Diwaniyah, Iraq
ABSTRACT
Background: Oxidative stress, defined as an imbalance between the production of free radicals and the body's ability to neutralize them with antioxidants, is a key contributor to the pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD). Malondialdehyde (MDA), a marker of lipid peroxidation, and the Ferric Reducing Ability of Plasma (FRAP), a measure of total antioxidant potential, are critical biomarkers for assessing oxidative stress in NAFLD. Objective: This study aimed to evaluate serum MDA and FRAP levels in NAFLD patients to explore their potential as biomarkers for oxidative stress and antioxidant status. Methodology: A case-control study was conducted from December 2023 to March 2024, involving 120 NAFLD patients (mean age 51.62 ± 11.25 years) and 60 healthy controls (mean age 50.15 ± 9.56 years). Serum MDA levels were measured as an indicator of lipid peroxidation, while FRAP levels were assessed to evaluate total antioxidant capacity. Results: NAFLD patients demonstrated significantly lower FRAP levels compared to the control group (p < 0.05), indicating reduced antioxidant potential. Conversely, MDA levels were significantly higher in the NAFLD group, reflecting increased oxidative stress and lipid peroxidation. Conclusion: Elevated MDA and reduced FRAP levels are strongly associated with oxidative stress in NAFLD patients. These findings highlight the potential utility of MDA and FRAP as biomarkers for monitoring disease progression and evaluating therapeutic interventions targeting oxidative stress in NAFLD.
Keywords: NAFLD, Malondialdehyde (MDA), Ferric-Reducing Ability of Plasma (FRAP) and Reactive Oxygen Species (ROS).
